ArticlePLoS neglected tropical diseases2025
Amplicon-based DNA sequencing to characterize Duffy antigen polymorphisms and analysis of Duffy blood system and glucose-6-phosphate dehydrogenase deficiency in Mauritania.
Article in PLoS neglected tropical diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundBoth Duffy blood antigen expression and G6PD deficiency are known to be associated with ethnic origin. Updates in epidemiological data on the prevalence of polymorphisms in these two human genes are key information for guiding national programs to eliminate Plasmodium vivax malaria.
methodsDuffy genotypes and their predicted phenotypes were determined in 943 blood samples from Mauritanian patients belonging to different ethnic groups (n = 432 White Moors and n = 511 individuals of black African ancestry) with a known G6PD genotype determined by PCR-restriction fragment length polymorphism in our previous study, using a cost-saving multiplexed barcoding technique that allows simultaneous analysis of a large number of samples and next-generation DNA sequencing (NGS).
resultsDuffy-negative phenotype predicted from Duffy genotype was predominant in individuals with black African ancestry (65-88%), while 16% of white Moors were Duffy-negative. Among 432 samples with interpretable Duffy sequence data from white Moors, 7/356 (2.0%) were Duffy-positive and G6PD A- deficient; 8/76 (10.5%) were Duffy-negative and G6PD A- deficient, mostly (n = 6) in heterozygous females. By contrast, among 511 patients of black African ancestry, 13 (13/140, 9.3% including heterozygous females) were Duffy-positive and G6PD A- deficient; 65 (65/371, 17.5%) were Duffy-negative and G6PD A- deficient, mostly (n = 44) in heterozygous females.
conclusionA large majority of white Moors are Duffy-positive and susceptible to P. vivax infection, but most are eligible for anti-hypnozoite therapy with primaquine at the standard dose. About 15.4% of individuals with black African ancestry were affected by G6PD A- deficiency, independently of their Duffy receptor status. This population requires G6PD screening before primaquine therapy in rare cases of P. vivax infection. These results provide important clues about the feasibility to implement an efficient anti-hypnozoite treatment in Mauritania and identify priority areas for targeted interventions against P. vivax malaria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.